- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/52 - Purines, e.g. adenine
Patent holdings for IPC class A61K 31/52
Total number of patents in this class: 2888
10-year publication summary
|
220
|
225
|
204
|
216
|
205
|
164
|
191
|
164
|
179
|
113
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Regents of the University of California | 20924 |
42 |
| Novartis AG | 10172 |
41 |
| Gilead Sciences, Inc. | 2249 |
32 |
| Merck Sharp & Dohme LLC | 3734 |
29 |
| Infinity Pharmaceuticals, Inc. | 96 |
28 |
| K36 Therapeutics, Inc. | 32 |
28 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3019 |
26 |
| Merck Sharp & Dohme Corp. | 2183 |
24 |
| F. Hoffmann-La Roche AG | 7792 |
22 |
| Boehringer Ingelheim International GmbH | 4480 |
21 |
| The Johns Hopkins University | 5948 |
20 |
| Dana-Farber Cancer Institute, Inc. | 2677 |
20 |
| Signal Pharmaceuticals, LLC | 175 |
20 |
| AstraZeneca AB | 2826 |
19 |
| Centre National de La Recherche Scientifique | 11122 |
19 |
| Amgen Inc. | 4486 |
19 |
| Epizyme, Inc. | 360 |
19 |
| Intellikine LLC | 41 |
18 |
| Rhizen Pharmaceuticals AG | 57 |
18 |
| Incyte Corporation | 1068 |
17 |
| Other owners | 2406 |